Hycult Biotech

Let's improve health! Leading manufacturer of antibodies, assays and proteins for innate immunity research. Specialized in complement and related diseases.

[Hycult Biotech @HycultBiotech]

A recent study using our ELISAs shows that PTX3 and sMR levels predict COVID-19 outcomes, survival, and long-term recovery. Previous work indicates that PTX3 and sMR also provide valuable insights into outcome of other infectious lung diseases. See also: https://t.co/j28Pi0ytbl

[Hycult Biotech @HycultBiotech]

Gut health matters! Introducing our Transgelin ELISA kit to assess severity of gut damage caused by acute intestinal ischemia, specifically by detecting disruptions in smooth muscle cells. Can be used with I-FABP, a biomarker for epithelial gut damage https://t.co/S8NSMLTPV4

[Hycult Biotech @HycultBiotech]

Introducing new ELISA kits developed to detect human Factor H-related proteins (FHR-2, FHR-3, FHR-4 and FHR-5). Kits are co-developed with @Sanquin within the @SciFiMed project, aiming to study the FH-protein family’s role in disease. See also: https://t.co/5CSodMXJk9

[Hycult Biotech @HycultBiotech]

Celebrating a remarkable achievement! Warm congratulations to Wim de Niet and Ronald de Niet on the 30th anniversary of Hycult Biotech and the 5th anniversary of Biocult. Here's to the continuation of a family legacy based on independence and collaborative partnerships.

[Hycult Biotech @HycultBiotech]

Exploring if complement dysregulation & low C7 levels link to Long Covid? Read this article suggesting C7 & TCC checks could unravel new insights. Contact us if you are interested in our prerelease C7 ELISA and related TCC products. https://t.co/dR2SDuzF5Y

[Hycult Biotech @HycultBiotech]

Translating biomarkers for clinical applications requires active participation in the field. @DiscoverieEU is a great multidisciplinary European project on IBS and comorbidity in which we try to resolve unmet needs for biomarker analysis.

[Hycult Biotech @HycultBiotech]

Interesting read: With the newly developed C1s/C1INH and MASP-1/C1INH complex assays it is shown for the first time that complement activation in random donor platelets is initiated via both the classical and lectin pathways. See Int J Mol Sci paper: https://t.co/7t2HCjwDB6

[Cambridge Bioscience @CambridgeBiosci]

Choosing a C3 #antibody for your research?

@HycultBiotech have put together a comprehensive guide to get you started.

Follow the link to read the guide:
https://t.co/eJZpxiZSCl

#Biotech #ScienceTwitter

[Hycult Biotech @HycultBiotech]

Discover our range of solutions and stay on the forefront of C3 research. We have collected C3 detection methods, tools, applications, and products. Find out more:

https://t.co/DcbEMNzOva

[Hycult Biotech @HycultBiotech]

With compliments of the complement team. Happy holidays!

[Hycult Biotech @HycultBiotech]

Making progress in our biomarker development quest for IBS and comorbidities. Do you want to learn more about this ambitious project and our WP8 contributions? Check: https://t.co/rDwC54PZeS

[Discoverie @DiscoverieEU]

This week was held the 3rd Steering Committee meeting of #DISCOvERIE. Heading towards a crucial phase of the project, we had great cross-WP discussions about preliminary findings on #IBS, mental & non-mental comorbidities, and our next steps for both #research & #dissemination.

[Hycult Biotech @HycultBiotech]

Discover the key to accurate complement analysis?
Navigating through complement analysis can be challenging. Explore our findings and get expert insights on our dedicated page. https://t.co/pbnHuKr9ZJ

[Hycult Biotech @HycultBiotech]

Combined workshop by Hycult and Microcoat on complement factor H related proteins detection by ELISA and LFA respectively. Measuring FHR2, FHR3 and FHR4 @SciFiMed meeting in Marburg.

[Loek Willems @Justloek]

Presenting our poster at joint Belgian-Dutch Immunology meeting. Highlighting our quantitative alternative pathway assay. Key features measuring complement inhibitors at high serum conditions and ruling out pathway interferences. See also https://t.co/4x5iJkvb6L

[Hycult Biotech @HycultBiotech]

New assays available now: Human Classical and Alternative Complement Pathway Assays
https://t.co/8foxwdk3mA

[Hycult Biotech @HycultBiotech]

Richard Pouw from Sanquin talking about Factor H, FHR and @SciFiMed work at Dutch Complement Symposium 2023. New FHR antibodies and ELISA also presented at Hycult table

[Loek Willems @Justloek]

Never lose your skills! Exciting to be back at the lab for one day after 18 years. Proving robustness of @hycultbiotech new quantitative complement pathway activity assays as well as inhibitor capacity of anti-C5 inhibitor (HM2414). Release data to follow soon!

[Hycult Biotech @HycultBiotech]

Catch up with our team at #ICW2023. We present interesting new tools for complement research, such as new pathway activation assays and first FHR antibodies from @SciFiMed project.

[Hycult Biotech @HycultBiotech]

Proud of our team's achievement of developing two new inhibiting antibodies for functional studies: Rat C5 and Human FGF2. https://t.co/VNsicrareM

[Hycult Biotech @HycultBiotech]

Introducing our brand new C3d ELISA kit! Neo-epitope specific ELISA that specifically distinguishes C3d from native C3 and other activated C3 proteins. Learn more today!

#Complement #C3d #Research #New #availablefromtoday #ELISA

https://t.co/iVy6bqyoud